| Size | Price | Stock | Qty |
|---|---|---|---|
| 2mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
EC50: 1.81 µM (IL-4)[1].
IL-4 (Interleukin-4). The compound binds directly to the IL-4 cytokine with a Kd value of 1.8 μM and inhibits IL-4 activity in cell-based assays. It exhibits selectivity for IL-4 over IL-13 (EC50 = 18.2 μM). The inhibition of IL-4 binding to its receptor (IL-4Rα) suppresses downstream JAK-STAT6 pathway activation. |
|---|---|
| ln Vitro |
Compound 52, known as IL-4-inhibitor-1, showed functional disruption of type II IL-4 binding in a cellular environment with low micromolar affinity[1]. Compound 52, also known as IL-4-inhibitor-1, demonstrates a dose-dependent decrease in pSTAT-6 levels, with an EC50 value of 3.1 µM. However, it had no effect on STAT-6 levels[1].
IL-4-inhibitor-1 displays low micromolar affinity and exhibits functional disruption of type II IL-4 binding in a cellular context. It inhibits IL-4 activity in a cell-based reporter assay with an EC50 of 1.81 μM. The compound demonstrates dose-dependent reduction in pSTAT-6 levels with an EC50 value of 3.1 μM in THP-1 monocytes, indicating inhibition of the IL-4-JAK1-STAT6 signaling pathway, but does not affect total STAT-6 levels. |
| ln Vivo |
No in vivo activity data has been reported for IL-4-inhibitor-1 in the available literature. As a small-molecule research compound, its in vivo efficacy, pharmacokinetic properties, and tolerability in animal models have not been characterized. Further preclinical studies would be required to evaluate its therapeutic potential in disease models of asthma, atopic dermatitis, and other IL-4-driven inflammatory conditions.
|
| Enzyme Assay |
Surface plasmon resonance (SPR) or similar biophysical assays are used to measure the direct binding affinity between IL-4-inhibitor-1 and recombinant IL-4 protein. The compound is titrated across immobilized IL-4 or vice versa to determine the equilibrium dissociation constant (Kd). For example, binding assays can determine a Kd value of 1.8 μM for the interaction with IL-4. Competitive binding experiments may also be performed to assess selectivity against related cytokines such as IL-13.
|
| Cell Assay |
Cell-based reporter assays are employed to evaluate the functional inhibition of IL-4 signaling. THP-1 human monocytic cells are stimulated with IL-4 in the presence of increasing concentrations of IL-4-inhibitor-1 (typically 0.1-100 μM). After incubation, the inhibition of STAT6 phosphorylation (pSTAT-6) is measured by Western blot or phospho-flow cytometry to determine the EC50. Alternatively, IL-4-dependent reporter cell lines expressing STAT6-responsive luciferase constructs can be used to quantify inhibition with an EC50 of 1.81 μM.
|
| Animal Protocol |
No animal experiments have been reported for IL-4-inhibitor-1 in the available literature. For small-molecule cytokine inhibitors of this class, typical in vivo efficacy studies would involve murine models of allergic airway inflammation (e.g., ovalbumin-induced asthma) or atopic dermatitis (e.g., MC903-induced skin inflammation), with compound administered via oral gavage or intraperitoneal injection, followed by assessment of inflammatory cell infiltration, cytokine levels, and histological analysis of target tissues.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of IL-4-inhibitor-1 have not been reported in the available literature. As a small-molecule compound with molecular weight 321.31 g/mol, it is expected to have oral bioavailability if optimized. Solubility data indicates good solubility in DMSO (50-90 mg/mL) and moderate solubility in ethanol (10 mg/mL). Powder stability is 3 years at -20°C and 2 years at 4°C. In solvent, stability is 6 months at -80°C and 1 month at -20°C.
|
| Toxicity/Toxicokinetics |
No toxicity data has been reported for IL-4-inhibitor-1 in the available literature. As a research-use-only compound, standard safety precautions should be observed when handling. The compound is not intended for human therapeutic use. Preliminary toxicity screening would typically involve assessment of cell viability in relevant cell lines, CYP450 inhibition profiling, and hERG channel binding studies to evaluate potential cardiotoxicity risks prior to in vivo studies.
|
| References | |
| Additional Infomation |
IL-4-inhibitor-1 (compound 52) is the first reported small-molecule inhibitor of the cytokine IL-4. The compound was described in ACS Chemical Biology in 2020. Its IUPAC name is 2-amino-4-(3,4-dihydroxyphenyl)-6-(4-fluorophenyl)pyridine-3-carbonitrile, with molecular formula C18H12FN3O2 and molecular weight 321.31. It is supplied as a solid with >98-99% purity for research purposes only, not for clinical use.
|
| Molecular Formula |
C18H12FN3O2
|
|---|---|
| Molecular Weight |
321.31
|
| Exact Mass |
321.091
|
| CAS # |
1332184-63-0
|
| PubChem CID |
136164931
|
| Appearance |
Light yellow to yellow solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
590.6±50.0 °C at 760 mmHg
|
| Flash Point |
311.0±30.1 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.729
|
| LogP |
3.17
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
24
|
| Complexity |
474
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC(=CC=C1C2=NC(=C(C(=C2)C3=CC(=C(C=C3)O)O)C#N)N)F
|
| InChi Key |
DWZPPBGRCDPFSS-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H12FN3O2/c19-12-4-1-10(2-5-12)15-8-13(14(9-20)18(21)22-15)11-3-6-16(23)17(24)7-11/h1-8,23-24H,(H2,21,22)
|
| Chemical Name |
2-amino-4-(3,4-dihydroxyphenyl)-6-(4-fluorophenyl)pyridine-3-carbonitrile
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (311.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (7.78 mM) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1123 mL | 15.5613 mL | 31.1226 mL | |
| 5 mM | 0.6225 mL | 3.1123 mL | 6.2245 mL | |
| 10 mM | 0.3112 mL | 1.5561 mL | 3.1123 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
